What is a clinical trial? Is participating in a clinical trial right for you? Learn more
Advanced Solid Tumors Clinical Trial
Have you or your loved ones been diagnosed with advanced solid tumors?
You may be eligible to participate in a advanced solid tumors clinical trial.
Have you or your loved ones been diagnosed with advanced solid tumors? You may be eligible to participate in a advanced solid tumors clinical trial.
Recruiting
Male
18 Years +
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the study of PT-112 in patients with thymoma and thymic carcinoma (Cohort A), and one cohort for the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC) (Cohort D).